
ECHO 4 PWS: Orthopedics
When: Tuesday, December 17, 2024 at 5:00 PM EST
Where: Virtual/Zoom Video
This series is for healthcare providers only
PWSA | USA's - ECHO 4 PWS Healthcare Provider Series
PWSA | USA launched our new Healthcare Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to healthcare professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.
Our next healthcare ECHO topic will take place on Tuesday, December 17, 2024, at 5:00 p.m. EST and will focus on Orthopedics and PWS presented by Dr. Harold van Bosse, followed by a 20-minute case study on PWS.
PWSA | USA’s Healthcare Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.
While this ECHO series is only for healthcare providers to attend, recordings of the webinars are available for our PWS families to view HERE.
Scroll below to find more ECHO 4 PWS webinar opportunities.
Speaker
Harold van Bosse, MD
ECHO 4 PWS is Sponsored By
LEarn More about PWS Research
Aardvark Therapeutics HERO Trial: U.S. Sites Now Open
Aardvark Therapeutics recently launched HERO, a global Phase 3 clinical trial investigating ARD-101, an innovative, orally administered treatment designed to help reduce hyperphagia (excessive hunger) and food-seeking behaviors in individuals with Prader-Willi syndrome (PWS). This randomized, double-blind, placebo-controlled trial is an important step toward identifying a potential new treatment option for the PWS community, and […]
Aardvark Therapeutics Launches HERO, A Phase 3 Trial of ARD-101 for Treatment of Hyperphagia in PWS; Now Enrolling Participants in the US
Aardvark Therapeutics recently launched HERO, a global Phase 3 randomized, double-blind, placebo-controlled clinical trial of ARD-101. ARD-101 is a novel, orally administered investigational therapy being studied to see if it can reduce excessive hunger and food-seeking behaviors in individuals with PWS. About the HERO Trial As part of the HERO study, participants will be randomly […]
Unlocking a New Path to Treat Hyperphagia in PWS: A Conversation with Aardvark Therapeutics
Hyperphagia, the relentless hunger that those living with Prader-Willi syndrome (PWS) experience, remains one of the most challenging and life-altering symptoms for individuals and families. But a promising investigational drug called ARD-101 is offering hope. In our April 29th episode of PWS United, Aardvark Therapeutics’ Dr. Tien Lee, M.D., CEO and Founder, and Dr. Manasi […]